Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study [Cancer Diagnostics]

CONCLUSIONS:
Pretherapeutic SHOX2 ccfDNA methylation testing allows for the identification of RCC patients at high risk of death after nephrectomy. These patients might benefit from an adjuvant treatment or early initiation of a palliative treatment.

Source: Clinical Chemistry - March 27, 2019 Category: Chemistry Authors: Jung, M., Ellinger, J., Gevensleben, H., Syring, I., Luders, C., de Vos, L., Putzer, S., Bootz, F., Landsberg, J., Kristiansen, G., Dietrich, D. Tags: Molecular Diagnostics and Genetics Cancer Diagnostics Source Type: research